Intra-Cellular Therapies (NASDAQ:ITCI) reported n/a earnings this Morning, coming in at ($0.56) per share, missing Wall Street’s estimates of ($0.50) per Share. Revenue for the quarter came in at $5.06 million beating analyst estimates of $0.05 million Recent Insider Trading for Intra-Cellular Therapies (NASDAQ:ITCI)
- On 2/16/2018 Lawrence J Hineline, VP, sold 49,700 with an average share price of $20.02 per share and the total transaction amounting to $994,994.00.
- On 1/22/2018 Michael Halstead, SVP, sold 25,500 with an average share price of $18.03 per share and the total transaction amounting to $459,765.00.
- On 1/8/2018 Kimberly E Vanover, SVP, sold 772 with an average share price of $17.46 per share and the total transaction amounting to $13,479.12.
- On 1/8/2018 Sharon Mates, Chairman, sold 6,604 with an average share price of $17.48 per share and the total transaction amounting to $115,437.92.
- On 1/5/2018 Kimberly E Vanover, SVP, sold 1,185 with an average share price of $17.37 per share and the total transaction amounting to $20,583.45.
- On 1/5/2018 Sharon Mates, Chairman, sold 11,257 with an average share price of $17.08 per share and the total transaction amounting to $192,269.56.
Recent Trading for Intra-Cellular Therapies (NASDAQ:ITCI) Shares of Intra-Cellular Therapies closed the previous trading session at 18.31 down -1.06 5.47% with 19.3700008392334 shares trading hands.